Bluejay Diagnostics (BJDX) Stock Price, News & Analysis

Company Overview

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Key Stats

• Today's Range: $3.35 to $3.65
• 50-Day Range: $3.33 to $4.99
• 52-Week Range: $3.03 to $386.72
• Volume: 18,584 shs
• Average Volume: 42,598 shs
• Market Capitalization: $1.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BJDX Stock Analysis - Frequently Asked Questions

How have BJDX shares performed this year?

Bluejay Diagnostics' stock was trading at $4.87 at the start of the year. Since then, BJDX stock has decreased by 29.2% and is now trading at $3.45.
View the best growth stocks for 2025 here.

How were Bluejay Diagnostics' earnings last quarter?

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($8.00) EPS for the quarter.

When did Bluejay Diagnostics' stock split?

Shares of Bluejay Diagnostics reverse split on Thursday, June 20th 2024. The 1-8 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

When did Bluejay Diagnostics IPO?

Bluejay Diagnostics (BJDX) raised $22 million in an initial public offering on Wednesday, November 10th 2021. The company issued 2,160,000 shares at a price of $10.00 per share.

How do I buy shares of Bluejay Diagnostics?

Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bluejay Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bluejay Diagnostics investors own include SoFi Technologies (SOFI), Athenex (ATNX), VF (VFC), Allarity Therapeutics (ALLR), Andersons (ANDE) and British American Tobacco (BTI).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 3/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BJDX
• CUSIP: N/A
• CIK: 1704287
• Web: www.bluejaydx.com
• Phone: 844-327-7078
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1,372.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,950,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -155.67%
• Return on Assets: -117.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.26
• Quick Ratio: 6.26

Sales & Book Value

• Annual Sales: $250,000.00
• Price / Sales: 7.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $934.50 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 550,000
• Free Float: 551,000
• Market Cap: $1.90 million
• Optionable: Not Optionable
• Beta: 0.46